抗精神病藥物市場(∼2017年):金普薩(Zyprexa)·安立復(Abilify)·思樂康(Seroquel)·哲思(Geodon)專利到期，及學名藥開始販售將限制開發平台分子商業機會的可能性

抗精神病藥物對精神分裂症及燥鬱症等所謂精神性疾病而言，依舊是標準性的治療法。抗精神病藥物市場的主要七個國家（美國、英國、西班牙、義大利、法國、德國、日本）2010年收益為140億800萬美金。主要的抗精神病藥專利到期，及學名藥的增加，一般認為抗精神病藥物市場，將從2010年的140億8000萬美金，以CAGR0.4%縮小到2017年的137億3300萬美金的規模。

本報告提供全球抗精神病藥物市場相關調查，提供市場規模，市場佔有率，年度治療費用，銷售額及治療上的利用模式相關市場數據分析，同時包含到2017年為止的市場預測，不同地區的市場情況，開發中產品及競爭情形等分析，為您概述為以下內容。

第1章 目錄

第2章 簡介

第3章 全球市場概要

• 簡介
• 收益預測
• 年度治療費用
• 主要的抗精神病藥物產品
  • 思樂康(Seroquel)
  • 金普薩(Zyprexa)
  • 安立復(Abilify)
  • 理思必妥(Risperdal)
  • 哲思(Geodon)
• 新的抗精神病藥
  • Fanapt (iloperidone)
  • Saphris / Sycrest (asenapine)
  • Invega Sustenna (Paliperidone Palmitate注射劑)
  • Latuda (lurasidone Hcl)

第4章 各地區情況

• 收益分析:各地區
• 美國
  • 收益
  • 年度治療費用
• 歐洲的前五名國家
  • 收益
  • 年度治療費用
• 日本 - 抗精神病藥市場
  • 收益
  • 年度治療費用

第5章 治療情況

• 躁鬱症 - 抗精神病藥市場
  • 簡介
  • 收益
  • 年度治療費用
• 躁鬱症抗精神病藥市場促進因素與阻礙因素
  • 促進因素
  • 阻礙要素
• 精神分裂症 - 抗精神病藥市場
  • 簡介
  • 收益
  • 年度治療費用
  • 治療的利用模式
• 精神分裂症抗精神病藥市場促進因素與阻礙因素
  • 促進因素
  • 阻礙要素

第6章 開發中產品分析

• 簡介
  • 發現階段的分子
  • 前臨床階段的分子
  • 第一階段的分子
  • 第2階段的分子
  • 第3階段的分子
  • 正處於新藥認証階段的分子

第7章 競爭情形

• 市場佔有率分析
  • AstraZeneca
  • Eli Lilly
  • Bristol-Myers Squibb (BMS)
  • Johnson & Johnson (J&J)
  • Pfizer

第8章 收購與合併情況

• 收購與合併交易(2007年∼2011年)
  • 各地區
  • 各交易金額
  • 各年度
  • 收購與合併交易的摘要(2009年∼2011年)
• 授權交易
  • 各地區
  • 各年度
  • 交易的摘要(2010年∼2011年)
• 共同開發交易
  • 各地區
  • 各年度
  • 交易的摘要(2010年∼2011年)

第9章 附錄

圖表

Summary

GBI Research analysis shows that antipsychotics remain the standard care for the treatment of mental disorders such as schizophrenia and bipolar disorder and generated $14,080m of revenue in 2010 in the top seven geographies including the US, the UK, Spain, Italy, France, Germany and Japan. Newer agents (atypical antipsychotics) such as AstraZeneca's Seroquel, Eli Lilly's Zyprexa, Bristol-Myers Squibb's Abilify, J&J's Risperdal and Pfizer's Geodon continued to dominate the global antipsychotics market and achieved blockbuster status due to their better efficacy. Schizophrenia represents 70% while bipolar disorder contributed 30% to the global antispychotics market. The patent expiries of leading antispychotics followed by the immediate entry of generic versions are expected to increase the price competition in the antipsychotic market. The market is expected to decline at a CAGR of 0.4% from $14,080m in 2010 to $13,733m in 2017.

Scope

• Data and analysis on the antipsychotics market in the leading geographies of the world - the US, the UK, Germany, France, Italy, Spain, and Japan.
• Annualized market data for the antipsychotics market from 2002 to 2010, with forecasts to 2017.
• Market data on the geographical landscape and therapeutic landscape, including market size, market share, annual cost of therapy, sales volume and treatment usage patterns such as disease population, treatment seeking population, diagnosis population and prescription population.
• Share of the generics in the global antipsychotics market and for the market of each indication that is covered in the report.
• Key drivers and restraints that have had a significant impact on the market.
• The competitive landscape of the global antipsychotic market including top companies benchmarking. The key companies studied in this report are Eli Lilly, Pfizer, AstraZeneca, Bristol-Myers Squibb and Johnson & Johnson.
• Key M&A activities and Licensing Agreements that took place in 2009 and 2010 in the antipsychotics market.

Reasons to buy

• Align their product portfolio to the markets with high growth potential.
• Build effective strategies to launch their pipeline products by identifying potential geographies.
• Exploit in-licensing and out-licensing opportunities by identifying products that might fill their portfolio gaps.
• Develop key strategic initiatives by studying the key strategies of top competitors.
• Devise a more tailored country strategy through the understanding of key drivers and barriers and market potential of each indication.
• Develop market-entry and market expansion strategies by identifying the geographic markets poised for strong growth.
• Reinforce R&D pipelines by identifying new target mechanisms which can produce first-in-class molecules which are safer and more efficacious.

GBI Research, the leading business intelligence provider, has released its latest research “Antipsychotics Market to 2017 - Patent Expiries for Zyprexa, Abilify, Seroquel and Geodon and the Launch of Generic Versions Will Limit Commercial Opportunities for Pipeline Molecules“, which provides insights into the global antipsychotics market until 2017. The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research's team of industry experts. The report provides an in-depth analysis of the antipsychotics market for bipolar disorder and schizophrenia. The report also provides the share of generics in the global antipsychotics market as well as in each indication market. The report examines the global bipolar disorder and schizophrenia treatment usage patterns. In addition, geographical distribution of the antipsychotic market across the US, the top five countries of Europe and in Japan is provided. The report also includes insights into the antipsychotics R&D product pipeline and explores the competitive landscape including major players in the antipsychotics market. Finally, the report also includes an analysis on the Mergers and Acquisitions (M&A) and licensing agreements that have recently taken place in the antipsychotics market.

Antipsychotic drugs remain the standard care for the treatment of mental disorders such as schizophrenia and bipolar disorder. The global antipsychotic market for such treatments is made up of 70% schizophrenia therapeutics and 30% bipolar disorder therapeutics.

The global antipsychotics market has shown a rising trend from 2002, growing at a Compound Annual Growth Rate (CAGR) of 4.8% to reach $14 billion in 2010. Newer agents (atypical antipsychotics) such as AstraZeneca's Seroquel (quetiapine fumarate), Eli Lilly's Zyprexa (olanzapine), Bristol-Myers Squibb's Abilify (aripiprazole), Johnson & Johnson's (J&J) Risperdal (risperidone) and Pfizer's Geodon (ziprasidone HCl) were rapidly adopted during this period due to their better efficacy when compared with typical antipsychotics and these drugs achieved blockbuster status.

However, the patent expiries of the leading antipsychotics such as Zyprexa, Abilify, Geodon, and Seroquel in the forecast period, followed by the immediate entry of generic versions are expected to increase price competition in the global antipsychotics market and so may limit the commercial opportunities to pipeline molecules. As a result the global antipsychotics market is expected to decline at a CAGR of 0.4% from $14 billion in 2010 to $13.8 billion in 2017.

The schizophrenia therapeutics market is highly competitive with many typical and atypical antipsychotics contributing to the market. The atypical antipsychotics are the more preferred drugs for the treatment of schizophrenia due to their better safety and efficacy profile.

The global schizophrenia therapeutics market generated revenues of about $9.9 billion in 2010 growing at a CAGR of 4.5% from $7 billion in 2002. This market is expected to witness price competition in the forecast period due to the series of patent expiries of major drugs such as Zyprexa (2011), Geodon (2012), Abilify (2015) and Saphris (2015). The launch of Latuda (lurasidone) has increased the burden of competition in an already highly competitive antipsychotics market in the US. The product pipeline of antipsychotics is comprised of many new molecules at various stages of clinical development. The expected launch of late stage molecules and the anticipated entry of generic drugs are expected to increase competition in the antipsychotics market in the future. The schizophrenia therapeutics market is estimated to decline at a CAGR of 0.4% from 2010 to 2017.

The US was the major contributor to the antipsychotics market in 2010 with a share of 58%.It was followed by the top five countries of Europe and Japan which accounted for 30% and 12% respectively. The high prevalence rates of schizophrenia and bipolar disorders among the growing geriatric population, comparatively better disease awareness and treatment seeking rate are some of primary reasons that made the US the leading contributor of the antipsychotics market in 2010.

However, the trend towards use of generics, reimbursement issues, patent expirations, safety issues and a reduction in inventive product launches have worsened the economic slowdown of this sector in the US. The generic drug segment is expected to see rapid growth due to the patent expiry of major antipsychotics which may result in limited commercial opportunities for pipeline molecules.

1. Table of Contents

• 1.1. List of Tables
• 1.2. List of Figures

2. Antipsychotics Market to 2017 - Introduction

• 2.1. GBI Report Guidance

3. Antipsychotics Market to 2017 - Global Market Overview

• 3.1. Introduction
• 3.2. Revenue Forecasts
  • 3.2.1. Generic Share
• 3.3. Annual Cost of Treatment
• 3.4. Top Antipsychotics Drug Products
  • 3.4.1. Seroquel (quetiapine)
  • 3.4.2. Zyprexa (olanzapine)
  • 3.4.3. Abilify (aripiprazole)
  • 3.4.4. Risperdal (risperidone)
  • 3.4.5. Geodon (ziprasidone)
• 3.5. Newer Antipsychotics
  • 3.5.1. Fanapt (iloperidone)
  • 3.5.2. Saphris / Sycrest (asenapine)
  • 3.5.3. Invega Sustenna (paliperidone palmitate extended release injectable suspension)
  • 3.5.4. Latuda (lurasidone Hcl)

4. Antipsychotics Market to 2017 - Geographical Landscape

• 4.1. Revenue Analysis by Geography
• 4.2. The US
  • 4.2.1. Revenue
  • 4.2.2. Annual Cost of Treatment
• 4.3. Top Five Countries of Europe
  • 4.3.1. Revenue
  • 4.3.2. Annual Cost of Treatment
• 4.4. Japan - Antipsychotics Market
  • 4.4.1. Revenue
  • 4.4.2. Annual Cost of Treatment

5. Antipsychotics Market to 2017 - Therapeutic Landscape

• 5.1. Bipolar Disorder - Antipsychotics Market
  • 5.1.1. Introduction
  • 5.1.2. Revenue
  • 5.1.3. Annual Cost of Treatment
  • 5.1.4. Treatment Usage Patterns
• 5.2. Drivers and Barriers to the Antipsychotics Market for Bipolar Disorder
  • 5.2.1. Drivers for Bipolar Disorder Therapeutics Market
  • 5.2.2. Barriers for Bipolar Disorder Therapeutics Market
• 5.3. Schizophrenia - Antipsychotics Market
  • 5.3.1. Introduction
  • 5.3.2. Revenue
  • 5.3.3. Annual Cost of Treatment
  • 5.3.4. Treatment Usage Patterns
• 5.4. Drivers and Barriers to the Antipsychotics Market for Schizophrenia
  • 5.4.1. Drivers for the Schizophrenia Therapeutics Market
  • 5.4.2. Barriers for the Schizophrenia Therapeutics Market

6. Antipsychotics Market to 2017 - Product Pipeline Analysis

• 6.1. Introduction
  • 6.1.1. Antipsychotics Market to 2017- Discovery Stage Molecules
  • 6.1.2. Antipsychotics Market to 2017- Pre-clinical Stage Molecules
  • 6.1.3. Antipsychotics Market to 2017- Phase I Stage Molecules
  • 6.1.4. Antipsychotics Market to 2017- Phase II Stage Molecules
  • 6.1.5. Antipsychotics Market to 2017- Phase III Stage Molecules
  • 6.1.6. Antipsychotics Market to 2017- NDA Filed Molecules
  • 6.1.7. NDA filed molecules

7. Antipsychotics Market to 2017 - Competitive Landscape

• 7.1. Market Share Analysis
  • 7.1.1. AstraZeneca
  • 7.1.2. Eli Lilly
  • 7.1.3. Bristol-Myers Squibb (BMS)
  • 7.1.4. Johnson & Johnson (J&J)
  • 7.1.5. Pfizer

8. Antipsychotics Market to 2017 - M&A Landscape

• 8.1. M&A Deals (2007-2011)
  • 8.1.1. M&A Deals by Region
  • 8.1.2. M&A Deals by Value
  • 8.1.3. M&A Deals by Year
  • 8.1.4. Summary of M&A Deals (2009-2011)
• 8.2. Licensing Deals
  • 8.2.1. Licensing Deals by Region
  • 8.2.2. Licensing Deals by Year
  • 8.2.3. Deal Summary (2010-2011)
• 8.3. Co-development Deals
  • 8.3.1. Co-development Deals by Region
  • 8.3.2. Co-development Deals by Year
  • 8.3.3. Deal Summary (2010 - 2011)

9. Antipsychotics Market to 2017 - Appendix

• 9.1. Market Definitions
• 9.2. Abbreviations
• 9.3. Research Methodology
  • 9.3.1. Coverage
  • 9.3.2. Secondary Research
  • 9.3.3. Primary Research
  • 9.3.4. Therapeutic Landscape
  • 9.3.5. Geographical Landscape
  • 9.3.6. Pipeline Analysis
  • 9.3.7. Competitive Landscape
  • 9.3.8. Expert Panel Validation
• 9.4. Contact Us
• 9.5. Disclaimer
• 9.6. Sources

• Table 1: Antipsychotics Market, Global, Revenue, ($m), 2002-2010
• Table 2: Antipsychotics Market, Global, Revenue Forecast, ($m), 2010-2017
• Table 3: Antipsychotics Market, Global, Annual Cost of Treatment ($), 2002-2010
• Table 4: Antipsychotics Market, Global, Annual Cost of Treatment ($), 2010-2017
• Table 5: Antipsychotics Market, Revenue of Leading Antipsychotics,($m),2008-2010
• Table 6: Antipsychotics Market, Newer Antipsychotics, 2009-2010
• Table 7: Antipsychotics Market, The US, Revenue ($m), 2002-2010
• Table 8: Antipsychotics Market, The US, Revenue Forecast ($m), 2010-2017
• Table 9: Antipsychotics Market, The US, Annual Cost of Treatment ($), 2002-2010
• Table 10: Antipsychotics Market, The US, Annual Cost of Treatment ($), 2010-2017
• Table 11: Antipsychotics Market, Top Five Countries of Europe, Revenue ($m), 2002-2010
• Table 12: Antipsychotics Market, Top Five Countries of Europe, Revenue Forecast ($m), 2010-2017
• Table 13: Antipsychotics Market, Top Five Countries of Europe, Annual Cost of Treatment ($), 2002-2010
• Table 14: Antipsychotics Market, Top Five Countries of Europe, Annual Cost of Treatment ($), 2010-2017
• Table 15: Antipsychotics Market, Japan, Revenue ($m), 2002-2010
• Table 16: Antipsychotics Market, Japan, Revenue Forecast ($m), 2010-2017
• Table 17: Antipsychotics Market, Japan, Annual Cost of Treatment ($), 2002-2010
• Table 18: Antipsychotics Market, Japan, Annual Cost of Treatment, ($), 2010-2017
• Table 19: Antipsychotics Market, Bipolar Disorder, Global, Revenue ($m), 2002-2010
• Table 20: Antipsychotics Market, Bipolar Disorder, Global, Revenue Forecast ($m), 2010-2017
• Table 21: Antipsychotics Market, Bipolar Disorder, Revenue by Country, ($m), 2002-2010
• Table 22: Antipsychotics Market, Bipolar Disorder, Revenue by Country, ($m), 2010-2017
• Table 23: Antipsychotics Market, Bipolar Disorder, Annual Cost of Treatment ($), 2002-2010
• Table 24: Antipsychotics Market, Bipolar Disorder, Annual Cost of Treatment ($), 2010-2017
• Table 25: Antipsychotics Market, Bipolar Disorder, Global, Treatment Usage Patterns (Thousand), 2002-2010
• Table 26: Antipsychotics Market, Bipolar Disorder, Global, Treatment Usage Patterns (Thousand), 2010-2017
• Table 27: Antipsychotics Market, Schizophrenia, Global, Revenue ($m), 2002-2010
• Table 28: Antipsychotics Market, Schizophrenia, Global, Revenue Forecast ($m), 2010-2017
• Table 29: Antipsychotics Market, Schizophrenia, Global, Revenue by Country, ($m), 2002-2010
• Table 30: Antipsychotics Market, Schizophrenia, Global, Revenue by Country, ($m), 2010-2017
• Table 31: Antipsychotics Market, Schizophrenia, Annual Cost of Treatment ($), 2002-2010
• Table 32: Antipsychotics Market, Schizophrenia, Annual Cost of Treatment ($), 2010-2017
• Table 33: Antipsychotics Market, Schizophrenia, Global, Treatment Usage Patterns (Thousand), 2002-2010
• Table 34: Antipsychotics Market, Schizophrenia, Global, Treatment Usage Patterns (Thousand), 2010-2017
• Table 35: Antipsychotics Market, Discovery Stage Molecules, 2011
• Table 36: Antipsychotics Market, Preclinical Stage Molecules, 2011
• Table 37: Antipsychotics Market, Phase I Stage Molecules, 2011
• Table 38: Antipsychotics Market, Phase II Stage Molecules, 2011
• Table 39: Antipsychotics Market, Phase III Stage Molecules, 2011
• Table 40: Antipsychotics Market, NDA Filed Molecules, 2011
• Table 41: Antipsychotics Market, Global, M&A Deals, 2007-2011
• Table 42: Antipsychotics Market, Global, Licensing Deals, 2007-2011
• Table 43: Antipsychotics Market, Global, Co-developments Deals, 2008-2011

• Figure 1: Antipsychotics Market, Global, Revenue Forecast, ($m), 2002-2017
• Figure 2: Antipsychotics Market, Global, Generic Share, (%), 2010 and 2017
• Figure 3: Antipsychotics Market, Global Annual Cost of Treatment ($), 2002-2017
• Figure 4: Antipsychotics Market, Revenue of Leading Antipsychotics,($m),2008-2010
• Figure 5: Antipsychotics Market, Revenue Analysis by Geography, (%), 2010
• Figure 6: Antipsychotics Market, The US, Revenue Forecast, ($m), 2002-2017
• Figure 7: Antipsychotics Market, The US, Annual Cost of Treatment ($), 2002-2017
• Figure 8: Antipsychotics Market, Top Five Countries of Europe, Revenue Forecast ($m), 2002-2017
• Figure 9: Antipsychotics Market, Top Five Countries of Europe, Annual Cost of Treatment ($), 2002-2017
• Figure 10: Antipsychotics Market, Japan, Revenue Forecast ($m), 2002-2017
• Figure 11: Antipsychotics Market, Japan, Annual Cost of Treatment ($), 2002-2017
• Figure 12: Antipsychotics Market, Bipolar Disorder, Treatment Algorithm, 2011
• Figure 13: Antipsychotics Market, Bipolar Disorder, Global, Revenue Forecast ($m), 2002-2017
• Figure 14: Antipsychotics Market, Bipolar Disorder, Revenue by Country, ($m), 2002-2017
• Figure 15: Antipsychotics Market, Bipolar Disorder, Annual Cost of Treatment ($), 2002-2017
• Figure 16: Antipsychotics Market, Bipolar Disorder, Global, Treatment Usage Patterns (Thousand), 2002-2017
• Figure 17: Antipsychotics Market, Bipolar Disorder, Global Market Drivers and Barriers, 2010-2017
• Figure 18: Antipsychotics Market, Schizophrenia, Treatment Algorithm, 2011
• Figure 19: Antipsychotics Market, Schizophrenia, Global, Revenue Forecast ($m), 2002-2017
• Figure 20: Antipsychotics Market, Schizophrenia, Global, Revenue by Country, ($m), 2002-2017
• Figure 21: Antipsychotics Market, Schizophrenia, Annual Cost of Treatment ($), 2002-2017
• Figure 22: Antipsychotics Market, Schizophrenia, Global, Treatment Usage Patterns (Thousand), 2002-2017
• Figure 23: Antipsychotics Market, Schizophrenia, Global Market Drivers and Barriers, 2010-2017
• Figure 24: Antipsychotics Market, Product Pipeline Molecules by Clinical Stages of Development, (%), 2011
• Figure 25: Antipsychotics Market, Product Pipeline Molecules by Indication, (%), 2011
• Figure 26: Antipsychotics Market, Global Market Share Analysis,(%),2011
• Figure 27: Antipsychotics Market, SWOT Analysis of AstraZeneca, 2010
• Figure 28: Antipsychotics Market, SWOT Analysis of Eli Lilly, 2010
• Figure 29: Antipsychotics Market, SWOT Analysis of Bristol-Myers Squibb, 2010
• Figure 30: Antipsychotics Market, SWOT Analysis of Johnson & Johnson, 2010
• Figure 31: Antipsychotics Market, SWOT Analysis of Pfizer, 2010
• Figure 32: Antipsychotics Market, Global, Strategic Consolidation, 2007-2011
• Figure 33: Antipsychotics Market, Global, M&A Deals by Region, 2007-2011
• Figure 34: Antipsychotics Market, Global, M&A Deals by Value ($m), 2007-2011
• Figure 35: Antipsychotics Market, Global, M&A Deals by Year, 2007-2011
• Figure 36: Antipsychotics Market, Global, Licensing Deals by Region, 2007-2011
• Figure 37: Antipsychotics Market, Global, Licensing Deals by Year, 2007-2011
• Figure 38: Antipsychotics Market, Global Co-development Deals by Region, 2008-2011
• Figure 39: Antipsychotics Market, Global, Co-development Deals by Year, 2008-2011
• Figure 40: GBI Research Market Forecasting Model